Publications by authors named "Luca Marcomigni"

Claim this Profile
R
Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer.
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Luca Marcomigni

Oncol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer.
Giulio Metro, Eleonora Gariazzo, Silvia Costabile, Sara Baglivo, Fausto Roila, Luca Marcomigni

Oncol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case.].
Francesca Marasciulo, Luca Marcomigni, Roberta Porreca, Laura Tomasello, Fausto Roila

Recenti Prog Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.
Biagio Ricciuti, Luca Marcomigni, Giulio Metro, Guido Bellezza, Emanuele Caselli

J Thorac Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
Giulio Metro, Gianluigi Lunardi, Chiara Bennati, Pietro Chiarini, Isabella Sperduti, Luca Marcomigni

J Neurooncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting EGFR and ALK in NSCLC: current evidence and future perspective.
Chiara Bennati, Luca Paglialunga, Biagio Ricciuti, Giulio Metro, Luca Marcomigni

Lung Cancer Manag· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.
Giulio Metro, Gianluigi Lunardi, Piero Floridi, Jennifer P Pascali, Luca Marcomigni

J Thorac Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple EWSR1-WT1 and WT1-EWSR1 copies in two cases of desmoplastic round cell tumor.
Roberta La Starza, Gianluca Barba, Valeria Nofrini, Tiziana Pierini, Valentina Pierini, Luca Marcomigni

Cancer Genet· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Giulio Metro, Rita Chiari, Simona Duranti, Annamaria Siggillino, Matthias J Fischer, Luca Marcomigni

Lung Cancer· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis